ORION BIOTECHNOLOGY PRESENTING NEW DATA AT THE GPCR DRUG DISCOVERY SUMMIT
22. März 2022 09:07 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, March 22, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today...
ORION ANNOUNCES THE RAPID LEAD OPTIMIZATION OF OB-004 - A CCR2 ANTAGONIST
30. November 2021 10:07 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug...
ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC
04. November 2021 11:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel...
ORION BIOTECHNOLOGY ADDS INDUSTRY LEADER TO BOARD OF DIRECTORS
31. August 2021 10:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company that is developing novel G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of...
ORION BIOTECHNOLOGY SECURES $11.5M SERIES A FINANCING
17. Juni 2021 11:03 ET
|
Orion Biotechnology Canada Ltd.
ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing. ...
ORION BIOTECHNOLOGY WELCOMES NEW MEMBERS OF SCIENTIFIC ADVISORY BOARD
13. April 2021 10:05 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, April 13, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage biotechnology company focused on precision engineering small protein therapeutics, today...
PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING
28. Januar 2021 10:48 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERY
14. Januar 2021 11:16 ET
|
Orion Biotechnology Canada Ltd.
Genève SWITZERLAND, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that...
Orion Biotechnology Successfully Completes Phase 1 Clinical Trial of a First-in-Class Precision Engineered Ligand Analog for HIV Prevention
15. Oktober 2020 10:07 ET
|
Orion Biotechnology Canada Ltd.
OTTAWA, Canada, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today...
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
30. Juli 2020 10:51 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...